Navigation Links
iCardiac Processes Volume of Data Equivalent to One Thousand Traditional Thorough QT Studies
Date:7/29/2009

Establishes New Throughput Standard in Cardiac Core Lab Industry

Rochester, NY (PRWEB) July 29, 2009 -- iCardiac Technologies, Inc., a leader in advanced cardiac safety biomarker development and automated QT analysis, announced that it has processed a total of 45 million cardiac cycles for agency facing studies in a single month utilizing the company's Highly Automated QT(sm) method. The total volume of data represents the same number of cardiac cycles as would traditionally be evaluated in approximately one thousand TQT studies.

"We are enthusiastic about our continued string of industry firsts," said Sasha Latypova, Executive Vice President. "Our clients are gaining significant benefits from our advanced ECG methods, rapid turnaround times and highly scalable core lab processing capacity to meet their drug development needs."

In October 2005, the FDA introduced a new guidance for industry (ICH E14) requiring the evaluation of pro-arrhythmic potential of new drugs by measuring the QT segment of ECGs collected in clinical trials. The dissatisfaction among pharmaceutical developers with the poor precision and high cost of the "gold standard" manual QT measurements has lead to efforts toward automating QT interval measurement.

About iCardiac Technologies
iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement, including Highly Automated QT, which has been validated by pharmaceutical companies and accepted by the FDA as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies. For more information, visit: www.icardiac.com.

###

Read the full story at http://www.prweb.com/releases/1000tqt/cardiacsafety/prweb2672624.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. iCardiac Selected by Top 10 Pharmaceutical Company
2. iCardiac Selected for Multiple Cardiac Safety Studies
3. iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company
4. iCardiac Reports Significant Revenue Growth and Profitability
5. Varian Medical Systems to Showcase a Wide Spectrum of New and Updated Products That Improve Radiotherapy Treatment Processes at 2009 AAPM Meeting
6. Bion Announces Approval of New U.S. Patent that Broadens Protection for the Companys Livestock Waste Environmental Treatment Processes
7. Event Alert: SPL R4 Compliance and its Impact on Regulatory Submission Processes
8. Authentidate Teams with Nortel to Enhance Hospital Patient Discharge and Placement Processes
9. Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio
10. Honeywell Technology Selected to Control Manufacturing Processes at Major U.S. Biotech Site
11. Experts at Healthcare Conference Support Investments in the Health of Work Culture and Care Processes, Not Just Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... At present, the Biotech sphere is in a ... volatility is what makes this industry interesting to consider. Here ... (NASDAQ: SNTA ), CTI BioPharma Corp. (NASDAQ: ... and Heat Biologics Inc. (NASDAQ: HTBX ). Sign ... these stocks at: http://www.activewallst.com/register/ ...
(Date:5/26/2016)... , May 26, 2016 Q ... that it will be a featured presenter at the 5th ... New York City at the Grand ... Corin , Q BioMed Inc. CEO, is scheduled to begin ... cover the company,s business strategy, recent developments and outline milestones ...
(Date:5/26/2016)... ... 26, 2016 , ... Kinder Scientific (KinderScientific.com), a leading animal ... the Company for the future. Kinder Scientific announces restructured ownership and additional ... appointed Chairman of the Board, Curtis D. Kinghorn has been appointed CEO/President and ...
(Date:5/25/2016)... ... May 25, 2016 , ... Thailand’s Board ... BIO 2016 in San Francisco. Located at booth number 7301, representatives from the ... questions and discuss the Thai biotechnology and life sciences sector. , Deputy ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
Breaking Biology News(10 mins):